Summit Therapeutics Inc SMMT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:19 AM EDT
4.54quote price arrow up+0.03 (+0.55%)
Volume
263,843
52 week range
1.50 - 5.39
Loading...
  • Open4.54
  • Day High4.63
  • Day Low4.44
  • Prev Close4.51
  • 52 Week High5.39
  • 52 Week High Date05/08/24
  • 52 Week Low1.50
  • 52 Week Low Date05/31/23

Key Stats

  • Market Cap3.183B
  • Shares Out701.98M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-1.26
  • YTD % Change73.37

KEY STATS

  • Open4.54
  • Day High4.63
  • Day Low4.44
  • Prev Close4.51
  • 52 Week High5.39
  • 52 Week High Date05/08/24
  • 52 Week Low1.50
  • 52 Week Low Date05/31/23
  • Market Cap3.183B
  • Shares Out701.98M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-1.26
  • YTD % Change73.37

RATIOS/PROFITABILITY

  • EPS (TTM)-1.54
  • P/E (TTM)-2.95
  • Fwd P/E (NTM)-18.21
  • EBITDA (TTM)-609.452M
  • ROE (TTM)-601.85%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-271,685.00%
  • Debt To Equity (MRQ)128.71%

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Summit Therapeutics Inc

 

Profile

MORE
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung...
Robert Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Mahkam Zanganeh
President, Co-Chief Executive Officer, Director
Manmeet Soni CPA
Chief Operating Officer, Director
Ankur Dhingra
Chief Financial Officer
Address
2882 Sand Hill Road, Suite 106
Menlo Park, CA
94025
United States